Effects of Continuous Dopaminergic Stimulation on Parkinson’s Disease Gait: A Longitudinal Prospective Study with Levodopa Intestinal Gel Infusion
Open Access
- 8 May 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 14 (4) , 843-853
Abstract
Background: Gait issues, including reduced speed, stride length and freezing of gait (FoG), are disabling in advanced phases of Parkinson’s disease (PD), and their treatment is challenging. Levodopa/carbidopa intestinal gel (LCIG) can improve these symptoms in PD patients with suboptimal control of motor fluctuations, but it is unclear if continuous dopaminergic stimulation can further improve gait issues, independently from reducing Off-time. Objective: To analyze before (T0) and after 3 (T1) and 6 (T2) months of LCIG initiation: a) the objective improvement of gait and balance; b) the improvement of FoG severity; c) the improvement of motor complications and their correlation with changes in gait parameters and FoG severity. Methods: This prospective, longitudinal 6-months study analyzed quantitative gait parameters using wearable inertial sensors, FoG with the New Freezing of Gait Questionnaire (NFoG-Q), and motor complications, as per the MDS-UPDRS part IV scores. Results: Gait speed and stride length increased and duration of Timed up and Go and of sit-to-stand transition was significantly reduced comparing T0 with T2, but not between T0-T1. NFoG-Q score decreased significantly from 19.3±4.6 (T0) to 11.8±7.9 (T1) and 8.4±7.6 (T2) (T1-T0 p = 0.018; T2-T0 p < 0.001). Improvement of MDS-UPDRS-IV (T0-T2, p = 0.002, T0-T1 p = 0.024) was not correlated with improvement of gait parameters and NFoG-Q from T0 to T2. LEDD did not change significantly after LCIG initiation. Conclusion: Continuous dopaminergic stimulation provided by LCIG infusion progressively ameliorates gait and alleviates FoG in PD patients over time, independently from improvement of motor fluctuations and without increase of daily dosage of dopaminergic therapy.Keywords
This publication has 43 references indexed in Scilit:
- DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's DiseaseMovement Disorders Clinical Practice, 2021
- Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on DyskinesiaMovement Disorders Clinical Practice, 2020
- Freezing of Gait and Its Levodopa ParadoxJAMA Neurology, 2020
- Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and SafinamideMovement Disorders Clinical Practice, 2020
- The New Freezing of Gait Questionnaire: Unsuitable as an Outcome in Clinical Trials?Movement Disorders Clinical Practice, 2020
- Levodopa/Carbidopa Intestinal Gel Infusion Therapy: Focus on Gait and BalanceMovement Disorders Clinical Practice, 2018
- Characterizing freezing of gait in Parkinson's disease: Models of an episodic phenomenonMovement Disorders, 2013
- Classification of gait disturbances: Distinguishing between continuous and episodic changesMovement Disorders, 2013
- How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scaleMovement Disorders, 2013
- Which dyskinesia scale best detects treatment response?Movement Disorders, 2013